Stroke risk factors and stroke prevention

Seminars in Neurology

Volumn 18, Issue 4, 1998, Pages 429-440

  Elkind, Mitchell S ^a,c   Sacco, Ralph L ^a,b,c  

^a Columbia University ^*  (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Cerebrovascular disorders; Epidemiology; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOLIPIN ANTIBODY; CHOLESTEROL; CLOPIDOGREL; DIPYRIDAMOLE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LUPUS ANTICOAGULANT; MEVINOLIN; ORAL ANTIDIABETIC AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; SIMVASTATIN; TICLOPIDINE; WARFARIN;

ALCOHOL CONSUMPTION; BLOOD PRESSURE REGULATION; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CAUSE OF DEATH; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISABILITY; DISEASE PREDISPOSITION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; UNITED STATES;

EID: 0032429906     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040896     Document Type: Review

References (134)

1. Brown RD, Whisnant JP, Sicks RD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-380
2. Wolf PA, D'Agostino RB, O'Neal MA, et al. Secular trends in stroke incidence and mortality: the Framingham Study. Stroke 1992;23:1551-1555
3. Sacco RL, Boden-Albala B, Gan R, et al. Stroke incidence among white, black, and Hispanic residents of an urban community. Am J Epidemiol 1998;147:259-268
4. Howard G, Anderson R, Sorlie P, et al. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks: the National Longitudinal Mortality Study. Stroke 1994;25:2120-2125
5. Gillum RF. Stroke in blacks. Stroke 1988;19:1-9
6. Kiely DK, Wolf PA, Cupples LA, et al. Familial aggregation of stroke: the Framingham Study. Stroke 1993;24:1366-1371
7. Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of stroke in twins. Stroke 1992;23:221-223
8. Joutel A, Corpechot C, Ducros A, et al. Notch mutations in CADASIL, an hereditary adult-onset condition causing stroke and dementia. Nature 1996;338:707-710
9. Natowicz M, Kelley RI. Mendelian etiologies of stroke. Ann Neurol 1987;22:175-192
10. Markus HS, Barley J, Lunt R, et al. Angiotensin-converting enzyme gene deletion polymorphism: a new risk factor for lacunar stroke but not carotid atheroma. Stroke 1995;26:1329-1333
11. Wilson PWF, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994;272:1666-1671
12. Couderc R, Mahieux F, Bailleul S, et al. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. A case-control study. Stroke 1993;24:661-664
13. Terry JG, Howard G, Mercuri M, et al. Apolipoprotein E polymorphism is associated with segment-specific extracranial carotid artery intima-media thickening. Stroke 1996;27:1755-1759
14. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917
15. Fisher M, Fernandez JA, Ameriso SF, et al. Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation. Stroke 1996;27:1163-6
16. McMahon S, Rodgers A. The epidemiological association between blood pressure and stroke: implications for primary and secondary prevention. Hypertens Res 1994;17(suppl 1): S23-32
17. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observtaional studies corrected for the regression dilution bias. Lancet 1990;335:765-774
18. Whisnant JP. Effectiveness versus efficacy of treatment of hypertension for stroke prevention. Neurology 1996;46:301-307
19. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988
20. Hypertension Detection and Follow-Up Program Cooperative Group: Five-year findings of the Hypertension Detecton and Follow-Up Program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982;247:633-638
21. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993;153:578-581
22. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264
23. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764
24. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994;271:840-844
25. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457
26. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5
27. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30 years of follow-up in the Framingham Study. JAMA 1985;254:3449-3453
28. Boston Area Anticoagulation Trial in Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511
29. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for the prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691
30. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke prevention in atrial fibrillation study, final results. Circulation 1991;84:527-539
31. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke: the Framingham Study. JAMA 1983;250:2942-2946
32. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257
33. Steering Committee of the PhysiciansÆ Health Study Research Group. Final report on the aspirin component of the ongoing physicanss health study. N Engl J Med 1989;321:129-135
34. Benjamin EJ, Plehn JF, D'Agostino RB, et al. Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med 1992;327:374-379
35. Roberts JK, Omarali I, Di Tullio MR, et al. Valvular strands and cerebral ischemia. Effect of demographics and strand characteristics. Stroke 1997;28:2185-2188
36. Petty GW, Orencia AJ, Khandheria BK, Whisnant JP. A population-based study of stroke in the setting of mitral valve prolapse: risk factors and infarct subtype classification. Mayo Clin Proc 1994;69:632-634
37. Cohnheim J. Thrombose und Embolie, Vorlesungen umber allgemeine Pathologie. In Handbuch für Arzte und Studierende. Vol. 1. Berlin: Hirschwald, 1877:134, 144-145
38. Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-1152
39. Di Tullio MR, Sacco RL, Gopal A, et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992;117:461-465
40. Hausmann D, Mügge A, Daniel WG. Identification of patent foramen ovale permitting paradoxical embolism. J Am Coll Cardiol 1995;26:1030-1038
41. Homma S, Di Tullio MR, Sacco RL, et al. Characteristics of patent foramen ovale associated with cryptogenic stroke: a biplane transesophageal study. Stroke 1994;25:582-586
42. Ende DJ, Chopra PS, Rao PS. Transcatheter closure of atrial septal defect or patent foramen ovale with the buttoned device for prevention of recurrence of paradoxical embolism. Am J Cardiol 1996;78:233-236
43. Devuyst G, Bougasslavsky J, Ruchat P, et al. Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology 1996;47:1162-1166
44. Homma S, Di Tullio MR, Sacco RL, et al. Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke 1997;28:2376-2381
45. Amarenco P, Duyckaerts C, Tzourio C, et al. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992;326:221-225
46. Amarenco P, Cohen A, Baudrimont M, Bousser MG. Transesophageal echocardiographic detection of aortic arch disease in patients with cerebral infarction. Stroke 1992;23:1005-1009
47. Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994;331:1474-1479
48. Johnson KG, Yano K, Kato H. Cerebral vascular disease in Hiroshima, Japan. J Chronic Dis 1967;20:545-559
49. Heyman A, Karp HR, Heyden S, et al. Cerebrovascular disease in the bi-racial population of Evans County, Georgia. Stroke 1971;2:509-518
50. Qizilbash N, Duffy SW, Warlow C, Mann J. Lipids are risk factors for ischaemic stroke: overview and review. Cerebrovasc Dis 1992;2:127-136
51. Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and 6-year mortality from stroke in the 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989;320:904-910
52. Benfante R, Yano K, Hwang L-J, et al. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke 1994;25:814-820
53. Ueshima H, Iida M, Shimamato T, et al. Multivariate analysis of risk factors for stroke. 8-year follow-up of farming villages in Akita, Japan. Prev Med 1980;9:722-740
54. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaiian Japanese men. The Honolulu Heart Study. Stroke 1980;11:14-20
55. Salonen R, Seppanen K, Rauramaa R, Salonen JT. Prevalence of carotid atherosclerosis and serum cholesterol levels in Eastern Finland Arteriosclerosis 1988;8:788-792
56. Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations. Associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991;134:250-260
57. Sutton-Tyrell K, Alcorn HG, Wolfson SK, et al. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke 1993;24:355-361
58. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender differences in the association of Lp (a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Biol 1996;16:471-478
59. Atkins D, Psaty BM, Koepsell TD, et al. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 1993;119:136-145
60. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovostatin and dietary therapy: A randomized, controlled clinical trial. Ann Intern Med 1996;124:548-556
61. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovostatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-1687
62. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
63. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009
64. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
65. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;26:3015-3023
66. Gorelick PB, Rodin MB, Langenberg P, et al. Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke: results of a case control study at three urban medical centers in Chicago, Illinois. Neurology 1989;39:339-343
67. Bonita R, Scragg R, Stewart A, et al. Cigarette smoking and risk of premature stroke in men and women. Br Med J 1987; 293:6-8
68. Abbott RD, Yin Yin MA, Reed DM, Yano K. Risk of stroke in male cigarette smokers. N Engl J Med 1986;315:717-720
69. Colditz GA, Bonita R, Stampfer MJ, et al. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med 1988; 318:937-941
70. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA 1988;259:1025-1029
71. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. Br Med J 1989;298:789-794
72. Kawachi I, Colditz G, Stampfer M, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993;269:232-236
73. Wolf PA, Belanger AJ, D'Agostino RB. Management of risk factors. Neurol Clin 1992;10:177-191
74. Abbott RD, Donahue RP, MacMahon SW, et al. Diabetes and the risk of stroke: the Honolulu Heart Program. JAMA 1987; 257:949-956
75. Barrett-Connor E, Khaw K. Diabetes mellitus: an independent risk factor for stroke. Am J Epidemiol 1988;128:116-124
76. Abel GA, Sacco RL, Lin IF, et al. Race-ethnic variability in etiologic fraction for stroke risk factors: The Northern Manhattan Stroke Study. Stroke 1998;29:277 (abstract)
77. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
78. Abbolt RD, Rodriguez BL, Burchfiel CM, Curb JD: Physical activity in older middle-aged men and reduced risk of stroke: the Honolulu Heart Program. Am J Epidemiol 1994;139:881-893
79. Kiely DK, Wolf PA, Cupples LA, et al. Physical activity and stroke risk: the Framingham Study. Am J Epidemiol 1994;140:608-620
80. Haheim LL, Holme I, Hjermann I, Leren P. Risk factors of stroke incidence and mortality: a 12-year follow-up of the Oslo Study. Stroke 1993;24:1484-1489
81. Manson JE, Stampfer MJ, Willet WC, et al. Physical activity and incidence of coronary heart disease and stroke in women. Circulation 1995;91(suppl):5
82. Lindenstrom E, Boysen G, Nyboe J. Lifestyle factors and risk of cerebrovascular disease in women: the Copenhagen City Heart Study. Stroke 1993;24:1468-1472
83. Gillum RF, Mussolino ME, Ingram DD. Physical activity and stroke incidence in women and men: the NHANES I Epidemiologic Follow-Up Study. Am J Epidemiol 1996;143:860-869
84. Sacco RL, Gan R, Boden-Albala B, et al. Leisure-time physical activity and ischemic stroke risk. The Northern Manhattan Stroke Study. Stroke 1998;29:380-387
85. Department of Health and Human Services. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington, DC: Department of Health and Human Services Publication PHS 91-50213, 1991
86. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402-407
87. Fisher M. Transient monocular blindness associated with hemiplegia. Trans Am Neurol Soc 1951;76:154-158
88. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarerectomy in symptomatic patients with high-grade stenosis. N Engl J Med 1991;325:445-453
89. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) stenosis. Lancet 1991;337:1235-1243
90. Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. JAMA 266:3289-3294, 1991
91. The CASANOVA Study Group. Carotid surgery versus medical therapy in asymptomatic carotid stenosis. Stroke 1991;22: 1229-1235
92. Hobson RW II, Weiss DG, Fields WS, et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. N Engl J Med 1993;328:221-227
93. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421-1428
94. Lanska DJ, Kryscio RJ. Endarterectomy for asymptomatic internal carotid artery stenosis. Neurology 1997;48:1481-1490
95. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-59
96. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;338:1345-1349
97. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054
98. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266
99. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220
100. Hass WK, Easton JD, Adams HP Jr., et al. A randomized trial comparing ticlopidine hydrochloride with with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507
101. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in palients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
102. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13
103. Donahue RP, Abbott RD, Reed DM, Yano K. Alcohol and hemorrhagic stroke: the Honolulu Heart Study. JAMA 1986;255: 2311-2314
104. Stampfer MJ, Colditz GA, Willett WA, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988;319:267-273
105. Tanaka H, Ueda Y, Hayashi M, et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982;13:62-73
106. Gill JS, Shipley MJ, Tsementzis SA, et al. Alcohol consumption-A risk factor for hemorrhagic and non-hemorrhagic stroke. Am J Med 1991;90:489-197
107. Klatsky AL, Armstrong MA, Friedman GD. Alcohol use and subsequent cerebrovascular disease hospitalizations. Stroke 1989; 20:741-746
108. Palomäki H, Kaste M. Regular light-to-moderate intake of alcohol and the risk of ischemic stroke: is there a beneficial effect? Stroke 1993;24:1828-1832
109. Sacco RL, Elkind MS, Boden-Albala B, et al. The protective effect of moderate alcohol consumption on ischemic stroke. JAMA 1999 (in press).
110. Rodgers H, Aitken PD, French JM, et al. Alcohol and stroke. A case-control study of drinking habits past and present. Stroke 1993;24:1473-7
111. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE Disorders. Ann Intern Med 1990;112:682-698
112. Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990;40:1181-1189
113. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1190-1196
114. Hess DC, Krauss J, Adams RJ, et al. Anticardiolipin antibodies. A study of frequency in TIA and stroke. Neurology 1991;41: 525-528
115. Nencini P, Baruffi MC, Abbate R, et al. Lupus anticoagulant anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;23:189-193
116. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are a risk factor for first ischemic stroke. Neurology 1993;43:2069-2073
117. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002
118. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989;16:623-625
119. McCully KS: Vascular pathology of homocystinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969;56:111-128
120. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentration and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-291
121. Malinow MR, Nieto FJ, Szklo M, et al. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993;87:1107-1113
122. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057
123. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398
124. Verhoef P, Hennekens CH, Malinow MR, et al. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924-1930
125. Alfthan G, Pekkanen J, Jauhainen M, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis 1994;106:9-19
126. Ridker P, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979
127. Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995;92:3397-3400
128. Wimmer MLJ, Sandmann-Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke 1996;27:2207-2210
129. Elkind MS, Jackson LA, Wang SP, et al. Elevated Chlamydia pneumoniae IgA titers are a risk factor for ischemic stroke. Cerebrovasc Dis (in press)A: Update.
130. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-636
131. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-407
132. Chockalingam A, Fodor JG. Cardiovascular risk factors in Newfoundland population and modification of their level through nonpharmacological intervention. J Cardiovasc Pharmacol 1990;16(suppl 8):S54-S56
133. Rose G. Strategy for prevention: lessons from cardiovascular disease. Br Med J 1981;282:1847-1851
134. Dunabibin DW, Sandercock PAG. Preventing stroke by the modification of risk factors. Stroke 1990;21(suppl IV):IV36-IV39